Lexicon Pharmaceuticals (LXRX) Nears Key HCM Readout On An Undervalued Narrative
Lexicon Pharmaceuticals (LXRX) recently completed patient randomization in its pivotal Phase 3 SONATA HCM trial of sotagliflozin for obstructive and non obstructive hypertrophic cardiomyopathy, setting up a key clinical readout expected in early 2027.
See our latest analysis for Lexicon Pharmaceuticals.
Against this SONATA HCM milestone, Lexicon Pharmaceuticals’ share price recently closed at US$2.34, with a 90 day share price return of 50.97% and a year to date share price return of 105.26%, while the 1 year total shareholder return is 118.69%, which suggests momentum has been building despite some shorter term pullbacks such as the 30 day share price return of 8.24%.
If you are looking for more ideas around cardiometabolic and related therapies, this could be a useful moment to see what else is moving in healthcare focused AI, starting with 40 healthcare AI stocks.
After a move like Lexicon Pharmaceuticals has just seen, the dilemma is familiar. Do you commit at today’s price and accept nearer term volatility, or hold back and wait for a pullback that may not come?
Most Popular Narrative: 37.9% Undervalued
On the most followed narrative, Lexicon Pharmaceuticals screens as undervalued, with a fair value of $3.77 against the recent close at $2.34. That gap is built on a very specific earnings and margin story.
Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non opioid treatment for diabetic peripheral neuropathic pain in over two decades, which could significantly impact future revenue growth and market share. The company is developing LX9851, a first in class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data, which could open new revenue streams and target high demand markets once the IND is submitted in 2025.
Want to understand why this narrative supports such a rich future earnings multiple for Lexicon Pharmaceuticals? The entire case hinges on a specific revenue ramp, a sharp margin reset and rising share count assumptions that all have to work together. The details matter.
Result: Fair Value of $3.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Lexicon Pharmaceuticals still faces real pressure if costly trials disappoint or if dependency on partners like Viatris and Novo Nordisk slows or reshapes expected milestone flows.
Find out about the key risks to this Lexicon Pharmaceuticals narrative.
Another View on Lexicon Pharmaceuticals Valuation
The fair value narrative suggests Lexicon Pharmaceuticals looks attractive around $2.34 with a modelled value of $3.77. Yet on a simple sales multiple, the picture is very different. Lexicon trades on a P/S of 14.9x, compared with 4.9x for the US pharmaceuticals industry and 3.9x for peers, while the fair ratio is 7.5x. That gap points to meaningful valuation risk if sentiment shifts back toward more typical sales multiples.
For a closer look at how this P/S gap fits into the broader valuation story, including what would need to change for the ratio to move nearer the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With both optimism around Lexicon Pharmaceuticals and clear concerns in play, you may want to act promptly and review the full picture for yourself. Start by weighing the balance of its 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Lexicon Pharmaceuticals?
If you stop with Lexicon Pharmaceuticals, you may miss other stocks that fit your style. Use the screeners below to spot opportunities that match your goals.
- Target resilient companies with stronger balance sheets by scanning the solid balance sheet and fundamentals stocks screener (48 results) that may better handle future shocks.
- Hunt for potential mispriced opportunities by reviewing the 49 high quality undervalued stocks that combine quality with more modest expectations.
- Prioritise steadier profiles by checking the 83 resilient stocks with low risk scores that score well on risk factors many investors overlook.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com